Jan Zernicke

Berlin, BE, Germany

Last Updated: 09/26/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 21 publications

Rapid and profound treatment response of difficult-to-treat rheumatoid arthritis to CD19 CAR T-cell therapy.

Rapid and profound treatment response of difficult-to-treat rheumatoid arthritis to CD19 CAR T-cell therapy.

Journal: EULAR rheumatology open
Published: August 01, 2026

CD19 CAR T cell therapy for treatment-refractory seropositive rheumatoid arthritis: a phase 1 trial.

CD19 CAR T cell therapy for treatment-refractory seropositive rheumatoid arthritis: a phase 1 trial.

Journal: Nature medicine
Published: March 20, 2026

Teclistamab-induced rapid remission in refractory Anti-Jo-1 Antisynthetase Syndrome.

Teclistamab-induced rapid remission in refractory Anti-Jo-1 Antisynthetase Syndrome.

Journal: Annals of the rheumatic diseases
Published: September 07, 2025

Daratumumab in systemic lupus erythematosus: a single-arm phase 2 trial.

Daratumumab in systemic lupus erythematosus: a single-arm phase 2 trial.

Journal: Nature communications
Published: July 11, 2025

Targeting autoimmunity with CD19-CAR T-cell therapy: efficacy and seroconversion in diffuse systemic sclerosis and rheumatoid arthritis.

Targeting autoimmunity with CD19-CAR T-cell therapy: efficacy and seroconversion in diffuse systemic sclerosis and rheumatoid arthritis.

Journal: Rheumatology (Oxford, England)
Published: December 11, 2024

Anti-CD19 CAR T cell therapy induces antibody seroconversion and complete B cell depletion in the bone marrow of a therapy-refractory patient with ANCA-associated vasculitis.

Anti-CD19 CAR T cell therapy induces antibody seroconversion and complete B cell depletion in the bone marrow of a therapy-refractory patient with ANCA-associated vasculitis.

Journal: Annals of the rheumatic diseases
Published: September 17, 2024

Characterization of Genetic Landscape and Novel Inflammatory Biomarkers in Patients With Adult-Onset Still's Disease.

Characterization of Genetic Landscape and Novel Inflammatory Biomarkers in Patients With Adult-Onset Still's Disease.

Journal: Arthritis & rheumatology (Hoboken, N.J.)
Published: December 10, 2023

Performance of commercial SARS-CoV-2 wild-type and Omicron BA.1 antibody assays compared with pseudovirus neutralization tests.

Performance of commercial SARS-CoV-2 wild-type and Omicron BA.1 antibody assays compared with pseudovirus neutralization tests.

Journal: Journal of clinical virology : the official publication of the Pan American Society for Clinical Virology
Published: February 21, 2023

Improvement of humoral immunity by repeated dose-intensified COVID-19 vaccinations in primary non- to low-responders and B cell deficient rheumatic disease patients.

Improvement of humoral immunity by repeated dose-intensified COVID-19 vaccinations in primary non- to low-responders and B cell deficient rheumatic disease patients.

Journal: Journal of autoimmunity
Published: October 22, 2022

Type of vaccine and immunosuppressive therapy but not diagnosis critically influence antibody response after COVID-19 vaccination in patients with rheumatic disease.

Type of vaccine and immunosuppressive therapy but not diagnosis critically influence antibody response after COVID-19 vaccination in patients with rheumatic disease.

Journal: RMD open
Published: August 08, 2022

Pausing methotrexate prevents impairment of Omicron BA.1 and BA.2 neutralisation after COVID-19 booster vaccination.

Pausing methotrexate prevents impairment of Omicron BA.1 and BA.2 neutralisation after COVID-19 booster vaccination.

Journal: RMD open
Published: August 03, 2022

Pausing methotrexate improves immunogenicity of COVID-19 vaccination in elderly patients with rheumatic diseases.

Pausing methotrexate improves immunogenicity of COVID-19 vaccination in elderly patients with rheumatic diseases.

Journal: Annals of the rheumatic diseases
Published: November 17, 2021
Showing 1-12 of 21

Last Updated: 09/26/2026